Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

Inclusion Criteria: * Men and women ≥ 50 years of age * Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD including juxtafoveal lesions that affect the fovea evidenced by Fluorescein Angiography in the study eye * Patient having been treated for at least 12 months with Ranibizumab (≥ 8 injections) * Patient with a PED \> 250 µm, defined by spectral domain optical coherent tomography (SD-OCT), measured at two consecutive visits before inclusion with any persisting sub retinal fluid at baseline * Patient affiliated to a social security scheme * Signed Informed Consent Exclusion Criteria: * Patient with subfoveal atrophy and/or atrophy with a diameter greater than 150µm in the subfoveal or juxtafoveal area * Patient with a subfoveal fibrosis * Subretinal hemorrhage that is either 50 percent or more of the total lesion area or 1 or more disc areas in size in the study eye. * Scar, fibrosis or atrophy making up \> 50% of total lesion in the study eye. * Presence of retinal pigment epithelial tears or rips involving the macula in the study eye. * History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye. * Presence of other causes of choroidal neovascularization, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study eye or clinical evidence of diabetic…